Xenetic Biosciences, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Xenetic Biosciences, Inc. on November 15, 2017. The company is incorporated in Nevada and is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Three primary proposals were voted upon at the Annual Meeting:
- Election of Directors: Stockholders approved the election of seven nominees. All directors received over 6 million votes in favor, with withheld votes ranging from 3,341 to 6,769.
- Equity Incentive Plan: Stockholders approved the Amended and Restated 2014 Equity Incentive Plan. The vote was 649,506 For, 10,132 Against, and 5,363,172 Abstained.
- Ratification of Auditors: Stockholders ratified the selection of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017. The vote was 6,022,662 For, with no votes Against and 148 Abstained.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that the Amended and Restated 2014 Equity Incentive Plan was adopted despite a high number of abstentions (5,363,172).
- Verification of the specific terms of the approved Equity Incentive Plan to understand potential dilution.
- Confirmation of the board composition following the election of the seven directors.